Format

Send to

Choose Destination
See comment in PubMed Commons below
Breast Cancer Res Treat. 2008 Feb;107(3):421-5. Epub 2007 Apr 24.

Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk.

Author information

1
Department of Epidemiology and Public Health, Yale University School of Medicine, LEPH Room 702, New Haven, CT 06520, USA. yong.zhu@yale.edu

Abstract

Three known non-synonymous polymorphisms (Ala394Thr, Ser471Leu and Pro690Ala) in the largest circadian gene, Neuronal PAS domain protein 2 (NPAS2), were genotyped in a breast cancer case-control study conducted in Connecticut, USA (431 cases and 476 controls). We found that women with the heterozygous Ala394Thr genotype were significantly associated with breast cancer risk compared to those with the common homozygous Ala394Ala (OR = 0.61, 0.46-0.81, P = 0.001). This is the first evidence demonstrating a role of the circadian gene NPAS2 in human breast cancer, suggesting that genetic variations in circadian genes might be a novel panel of biomarkers for breast cancer risk.

PMID:
17453337
PMCID:
PMC2366999
DOI:
10.1007/s10549-007-9565-0
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center